These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1023 related items for PubMed ID: 9532413

  • 1. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
    Dahlborg SA, Petrillo A, Crossen JR, Roman-Goldstein S, Doolittle ND, Fuller KH, Neuwelt EA.
    Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
    [Abstract] [Full Text] [Related]

  • 2. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
    Jahnke K, Kraemer DF, Knight KR, Fortin D, Bell S, Doolittle ND, Muldoon LL, Neuwelt EA.
    Cancer; 2008 Feb 01; 112(3):581-8. PubMed ID: 18072268
    [Abstract] [Full Text] [Related]

  • 3. Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy.
    Dahlborg SA, Henner WD, Crossen JR, Tableman CM, Petrillo A, Braziel R, Neuwelt EA.
    Cancer J Sci Am; 1996 Feb 01; 2(3):166-74. PubMed ID: 9166517
    [Abstract] [Full Text] [Related]

  • 4. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.
    McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA.
    Neurosurgery; 2000 Jan 01; 46(1):51-60; discussion 60-1. PubMed ID: 10626935
    [Abstract] [Full Text] [Related]

  • 5. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
    Fortin D, Desjardins A, Benko A, Niyonsega T, Boudrias M.
    Cancer; 2005 Jun 15; 103(12):2606-15. PubMed ID: 15880378
    [Abstract] [Full Text] [Related]

  • 6. Intensive cisplatin and cyclophosphamide-based chemotherapy without radiotherapy for intracranial germinomas: failure of a primary chemotherapy approach.
    Kellie SJ, Boyce H, Dunkel IJ, Diez B, Rosenblum M, Brualdi L, Finlay JL.
    Pediatr Blood Cancer; 2004 Aug 15; 43(2):126-33. PubMed ID: 15236278
    [Abstract] [Full Text] [Related]

  • 7. Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study.
    da Silva NS, Cappellano AM, Diez B, Cavalheiro S, Gardner S, Wisoff J, Kellie S, Parker R, Garvin J, Finlay J.
    Pediatr Blood Cancer; 2010 Mar 15; 54(3):377-83. PubMed ID: 20063410
    [Abstract] [Full Text] [Related]

  • 8. Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given with osmotic blood-brain barrier disruption in a rodent model: the issue of sequence.
    Remsen LG, McCormick CI, Sexton G, Pearse HD, Garcia R, Neuwelt EA.
    Clin Cancer Res; 1995 Jul 15; 1(7):731-9. PubMed ID: 9816039
    [Abstract] [Full Text] [Related]

  • 9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 15; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 10. Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy.
    Jennings MT, Cmelak A, Johnson MD, Moots PL, Pais R, Shyr Y.
    Pediatr Blood Cancer; 2004 Jul 15; 43(1):46-54. PubMed ID: 15170889
    [Abstract] [Full Text] [Related]

  • 11. Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption.
    Neuwelt EA, Gilmer-Knight K, Lacy C, Nicholson HS, Kraemer DF, Doolittle ND, Hornig GW, Muldoon LL.
    Pediatr Blood Cancer; 2006 Aug 15; 47(2):174-82. PubMed ID: 16086410
    [Abstract] [Full Text] [Related]

  • 12. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
    Thorarinsdottir HK, Rood B, Kamani N, Lafond D, Perez-Albuerne E, Loechelt B, Packer RJ, MacDonald TJ.
    Pediatr Blood Cancer; 2007 Mar 15; 48(3):278-84. PubMed ID: 16456857
    [Abstract] [Full Text] [Related]

  • 13. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group.
    Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, Broxson E, Donahue B, Finlay JL, Goldwein JW, Heier LA, Johnson D, Mazewski C, Miller DC, Packer R, Puccetti D, Radcliffe J, Tao ML, Shiminski-Maher T, Children's Cancer Group.
    J Clin Oncol; 2005 Oct 20; 23(30):7621-31. PubMed ID: 16234523
    [Abstract] [Full Text] [Related]

  • 14. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis.
    Fortin D, Gendron C, Boudrias M, Garant MP.
    Cancer; 2007 Feb 15; 109(4):751-60. PubMed ID: 17211866
    [Abstract] [Full Text] [Related]

  • 15. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
    Häberle B, Bode U, von Schweinitz D.
    Klin Padiatr; 2003 Feb 15; 215(3):159-65. PubMed ID: 12778356
    [Abstract] [Full Text] [Related]

  • 16. Primary chemotherapy for intracranial nongerminomatous germ cell tumors: results of the second international CNS germ cell study group protocol.
    Kellie SJ, Boyce H, Dunkel IJ, Diez B, Rosenblum M, Brualdi L, Finlay JL.
    J Clin Oncol; 2004 Mar 01; 22(5):846-53. PubMed ID: 14990640
    [Abstract] [Full Text] [Related]

  • 17. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors.
    Duffner PK, Horowitz ME, Krischer JP, Friedman HS, Burger PC, Cohen ME, Sanford RA, Mulhern RK, James HE, Freeman CR.
    N Engl J Med; 1993 Jun 17; 328(24):1725-31. PubMed ID: 8388548
    [Abstract] [Full Text] [Related]

  • 18. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors.
    Choi LM, Rood B, Kamani N, La Fond D, Packer RJ, Santi MR, Macdonald TJ.
    Pediatr Blood Cancer; 2008 May 17; 50(5):970-5. PubMed ID: 17941070
    [Abstract] [Full Text] [Related]

  • 19. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience.
    Fangusaro J, Finlay J, Sposto R, Ji L, Saly M, Zacharoulis S, Asgharzadeh S, Abromowitch M, Olshefski R, Halpern S, Dubowy R, Comito M, Diez B, Kellie S, Hukin J, Rosenblum M, Dunkel I, Miller DC, Allen J, Gardner S.
    Pediatr Blood Cancer; 2008 Feb 17; 50(2):312-8. PubMed ID: 17668858
    [Abstract] [Full Text] [Related]

  • 20. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors.
    Stern JW, Bunin N.
    Med Pediatr Oncol; 2002 Sep 17; 39(3):163-7. PubMed ID: 12210444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.